Silo Pharma has entered into a sponsored research agreement with the University of Maryland to develop and explore the potential of a targeted therapy delivery system for multiple sclerosis (MS). The company and investigators at the Baltimore university will test a targeted therapy delivery approach that uses peptides — short chains of amino acids, the building blocks of proteins — to guide different therapeutic agents to the central nervous system (CNS; the brain and spinal cord).…

You must be logged in to read/download the full post.